Memantine Found Effective Against Alzheimer’s
|LE Magazine November 2004|
|Memantine Found Effective Against Alzheimer’s|
The journal Clinical Drug Investigation recently reported that memantine is a cost-effective treatment for Alzheimer’s disease.
In July 2001, Life Extension reported that German doctors were using memantine successfully to treat Alzheimer’s patients, and expressed frustration with the FDA’s slowness in approving the medication.1 In October 2003, the FDA finally approved memantine for the treatment of moderate to severe Alzheimer’s disease. Memantine is marketed in the US by Forest Laboratories under the trade name Namenda™.
Memantine is an N-methyl- D-aspartate (NMDA) receptor antagonist that is neuroprotective by blocking glutamate, which can cause overstimulation of the nerves and become toxic to the nervous system. Memantine may benefit individuals with Alzheimer’s disease by improving cognition and overall functioning.
According to the Clinical Drug Investigation study, the costs of treating patients with moderate to severe Alzheimer’s disease with memantine are more than offset by the overall savings in patient care.2 A mathematical simulation estimated the cost implications of using memantine relative to no drug therapy over the course of five years in Alzheimer’s patients in Finland.
As expected, the initial cost of memantine therapy was greater than that of no therapy. As the study progressed, however, treatment with memantine reduced the costs of patient care by helping patients remain at home longer, thus delaying their need for care at a hospital or nursing home. Memantine therapy was associated with approximately four extra months of independence, one additional month of residence in the community, and a cost reduction over placebo of $2,050 per patient over five years (based on 2001 costs).
Alzheimer’s is the leading cause of dementia in the elderly, affecting 4 million Americans.
—Elizabeth Wagner, ND
1. Available at: http://www.lef.org/magazine/mag2001/july2001_report_brain_01.html. Accessed August 24, 2004.
2. Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer’s disease: A Markov Model in Finland. Clinical Drug Investigation. 2004 Jul;24(7):373-384.
|Curcumin Analogs Have Anti-Cancer Effects|
Scientists at Emory University in Atlanta have synthesized several chemical compounds based on curcumin that demonstrate extremely promising anti-cancer activity in the laboratory.
Curcumin, a bioactive compound present in turmeric, is known to exhibit powerful anti-cancer, anti-inflammatory, and antioxidant properties, and is believed to reduce the risk of cancer, heart disease, and Alzheimer’s disease. In laboratory tests performed at the National Cancer Institute, at least nine of more than a dozen laboratory-created curcumin analogs showed “a moderate degree of anti-cancer activity,” according to the Emory researchers.* Three of the new curcumin derivatives “exhibited a high degree of cytotoxicity,” inhibiting tumor cell growth better than the commonly used chemotherapy drug cisplatin.
In laboratory tests at Emory, eight of the new compounds exhibited “a high degree” of anti-cancer activity, including effectiveness at preventing or interfering with angiogenesis, the process by which tumors supply themselves with nutrients that fuel further growth. Anti-angiogenic activity is of special interest to oncologists, as eliminating the vessels that supply blood to a tumor effectively strangles the tumor while preventing damage to surrounding tissues.
Of the numerous potentially effective synthetic compounds, one deemed especially promising was tested on live mice bred to serve as human breast cancer models. The chemical was well tolerated by the rodents and effectively reduced the size of their tumors. Researchers believe that this curcumin analog may be a candidate for development as a new anti-cancer drug.
* Adams BK, Ferstl EM, Davis MC, et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem. 2004 Jul 15;12(14):3871-83.
|Vitamin E-CoQ10 Combo Reduces Inflammation|
Inflammation is common to many of today’s most prevalent health disorders, including heart disease, cancer, autoimmune disease, and diabetes. In a recent study, the combination of supplemental vitamin E and coenzyme Q10 (CoQ10) had the effect of reducing inflammatory status in baboons.*
The baboons were maintained on a baseline diet low in fat and cholesterol for three months, then were placed on a high-fat, high-cholesterol diet for seven weeks. Blood levels of C-reactive protein, an important marker for inflammation in the body and a significant predictor of cardiovascular disease risk, were mea-sured before and after the high-fat, high-cholesterol diet. The baboons’ serum C-reactive protein levels were unchanged after the high-fat, high-cholesterol diet challenge.
Next, the baboons were supplemented with the antioxidant vitamin E for two weeks. Serum C-reactive protein levels dropped significantly following vitamin E supplementation. CoQ10 was then added to the baboons’ supplementation, producing even greater reductions in inflammatory status as measured by C-reactive levels.
Vitamin E and CoQ10 may be powerful partners in reducing inflammatory status and thus in modulating the risk of numerous health conditions associated with inflammation and oxidative stress. Through their activity in reducing C-reactive protein, vitamin E and CoQ10 may help promote health and freedom from illnesses ranging from heart disease to diabetes.
—Elizabeth Wagner, ND
* Wang XL, Rainwater DL, Mahaney MC, Stocker R. Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons. Am J Clin Nutr. 2004 Sep;80(3):649-55.
|Vote “Yes” To Fund Stem Cell Research In California|
Stem cell research could lead to the reversal of aging and cures for diabetes, Parkinson's disease, multiple sclerosis, spinal cord injuries, Alzheimer's disease, AIDS and other diseases and conditions. The problem is that—for political reasons—stem cell research has been limited severely in the U.S. by federal restrictions. The government's reactionary position on stem cell research has also made it difficult for private companies to raise money for research on this revolutionary breakthrough.
Proposition 71 – The California Stem Cell and Cures Initiative is designed to close this funding gap, so that medical researchers can conduct lifesaving stem cell research in California. Prop 71 authorizes low-interest, tax-free state bonds that will provide an average of $295 million per year over a 10-year period for stem cell research. It specifically authorizes the funding of embryonic stem cell research, including cells derived from cloned embryos, which could lead to young cells, tissues and organs being transplanted into aging people without rejection by their immune systems. (For a greater understanding of the enormous potential of this technology, see the cover stories in the June 2000 and March 2002 issues of Life Extension Magazine)
If Prop 71 passes on election day, it will not only provide for extensive funding of lifesaving stem cell research in California, it will also encourage other states to fund this type of research, will put pressure on the federal government to lift its restrictions on stem cell research, will encourage venture capitalists to fund companies doing this research, and will encourage other countries to fund the research. It will be a major step forward in our quest for longer, healthier lives.
How You Can Help To Pass Prop 71
It is imperative that you take action to support the passage of The California Stem Cell and Cures Initiative (Prop 71).Your life and the lives of your loved ones are at stake.